UK Biotech Fundraising Shrinks In Q3 As Brexit Looms
BIA urges government to help by boosting life science funding
UK biotechs kept raising significant new funds last quarter but the rate slowed amid Brexit worries.
You may also be interested in...
PPF has bought a big stake in the UK-based T-cell specialist, one of many firms backed by investor Neil Woodford which have suffered stock slides in the past few months.
After receiving major backing for its strategy of targeting clonal neoantigens, Achilles's CEO tells Scrip that the UK firm's manufacturing prowess gives it an edge over competitors.
Created when BetterLife bought Altum at end-July, the merged entity will now focus on advancing the acquired group’s lead asset, an inhaled form of its patented interferon a2b product, as an early treatment for COVID-19.